The next step is to see if the process works and
is safe in human cells.
Not exact matches
«We've
been hearing about their potential for more than a decade, but the results have always
been in mice and rats, and no one has shown they
're safe or effective
in humans long term,» says Robert Lanza of Advanced
Cell Technology in Marlborough, Massachusetts, the company that carried out the stem cell intervent
Cell Technology
in Marlborough, Massachusetts, the company that carried out the stem
cell intervent
cell intervention.
Researchers
in optogenetics can control genetically modified brain
cells using light but because of these modifications, the technique
is not yet deemed
safe to use
in humans.
Tests
in mice and nonhuman primates had shown TGN1412 to
be safe, but when it
was injected into
humans —
in a dose less than 1/500 of what
was given to monkeys — it caused a massive release of infection - fighting T
cells that overstimulated the patients» immune systems, resulting
in multiple organ failure.
Neither group saw
cells developing into anything but brain
cells, but more studies will
be needed before the technique can
be considered
safe to test
in humans.
He and others have recently used gene - editing tools to correct mutations
in human iPS
cells but haven't used the same combination of methods or done the same set of experiments to determine whether the iPS - derived
cells are safe.
Allogeneic Mesenchymal Stem
Cells Stimulate Cartilage Regeneration and
Are Safe for Single - Stage Cartilage Repair
in Humans upon Mixture with Recycled Autologous Chondrons.
Clearly, researchers
are quickly overcoming the hurdles to using iPS
cells in human clinical trials, though issues still remain to
be addressed to ensure their
safe use
in regenerative medicine.
«
In a report published in the journal Lancet, scientists led by Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, provide the first evidence that stem cells from human embryos can be a safe and effective source of therapies for two types of eye diseases&raqu
In a report published
in the journal Lancet, scientists led by Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, provide the first evidence that stem cells from human embryos can be a safe and effective source of therapies for two types of eye diseases&raqu
in the journal Lancet, scientists led by Dr. Robert Lanza, chief scientific officer at Advanced
Cell Technology, provide the first evidence that stem
cells from
human embryos can
be a
safe and effective source of therapies for two types of eye diseases»
These same challenges exist for
human allergy suffers, but recently there has
been a major breakthrough
in the development of a new,
safe and effective therapy using a monoclonal antibody that specifically binds and neutralizes
human IgE that
is responsible for activating inflammation - producing
cells.